This content is only available within our institutional offering.
16 Feb 2026
Singer Capital Markets - SkinBio Therapeutics - On-going investigation creates near-term uncertainty
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Singer Capital Markets - SkinBio Therapeutics - On-going investigation creates near-term uncertainty
SkinBioTherapeutics Plc (SBTX:LON) | 5.2 0 (-12.5%) | Mkt Cap: 13.6m
- Published:
16 Feb 2026 -
Author:
Karl Keegan -
Pages:
3 -
Following Friday’s announcement that the CEO had resigned and an investigation into financial matters was underway, further information has arisen. As a result of the Board’s investigation and the subsequent expected removal of the FY25 accrued royalty income, the Board now anticipates that the results for the year ended 30 June 2026 will be significantly below current market expectations. Given that the investigation has not finally concluded, we prudently suspend our forecasts, withdraw our TP and move to under review.